Navigation Links
Curing arthritis in mice
Date:8/6/2014

chers studied the fusion molecule in combination with dexamethasone, a cortisone-like anti-inflammatory drug that is already used to treat rheumatoid arthritis in humans. The researchers started treating each mouse as soon as they began showing signs of the disease in the form of swollen extremities.

Clinical trials in the next year

When used separately, the new fusion molecule and dexamethasone managed only to slow the progression of the disease in the affected animals. In contrast, the typical signs of arthritis, such as swollen toes and paws, disappeared completely within a few days when both medications were administered at the same time. Concentrations of a whole range of immune messengers in blood and inflamed tissue, which are changed in rheumatoid arthritis, returned to their normal levels. "In our mouse model, this combined treatment creates a long-term cure," says Hemmerle, who, since completing her dissertation, has been working at Philochem, where she continues the project.

Based on the promising results from the animal model, Philochem is currently preparing to test the new drug in clinical trials on people suffering from rheumatoid arthritis. According to the researchers, these tests will begin in the next year.


'/>"/>

Contact: Teresa Hemmerle
teresa.hemmerle@pharma.ethz.ch
41-435-448-804
ETH Zurich
Source:Eurekalert

Page: 1 2

Related biology news :

1. Curing coronavirus with curiosity
2. Conference on securing the future supply of food: Challenges and opportunities
3. Mass. Eye and Ear announces Curing Kids Fund grant recipients
4. New class of anti-arthritis drugs effectively treats multiple inflammatory diseases
5. Stem cell mobilization therapy may effectively treat osteoarthritis
6. Grape consumption may offer benefits for symptomatic knee osteoarthritis
7. Drink milk? Women who do may delay knee osteoarthritis
8. Genetics can explain why infections can trigger rheumatoid arthritis
9. Researchers pursuing arthritis protein
10. Researchers complete a milestone in defining the genetic basis of rheumatoid arthritis
11. Rheumatoid arthritis research shows the potential of large-scale genetic studies for drug discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , Chine, 31 juillet 2015 ... www.icg-10.org ) sera organisée par le BGI ... Shenzhen en Chine. ... Depuis son inauguration en 2006, l,ICG est devenue ... dans le domaine des « omiques » et c,est aussi ...
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
(Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... 2002-2003 was short-lived, but a novel type of human coronavirus ... humans and bats alike, a fact that could make the ... to be published in in mBio , the online ... 11. The new coronavirus, called hCoV-EMC, is blamed for five ...
... change, deforestation and toxic waste, the assumption has been that ... from the University of California, Berkeley, suggests that such viewpoints ... need to be better stewards of the land are couched ... "sanctity" of Earth and our bodies. A UC Berkeley ...
... Auditory systems differ between sexes in sparrows depending ... found. The work adds to our knowledge of how ... humans, are able to change. Megan Gall, a ... peripheral auditory systems of male and female house sparrows, ...
Cached Biology News:New coronavirus has many potential hosts, could pass from animals to humans repeatedly 2New coronavirus has many potential hosts, could pass from animals to humans repeatedly 3Conservatives can be persuaded to care more about the environment 2Conservatives can be persuaded to care more about the environment 3Researcher finds gender differences in seasonal auditory changes 2
(Date:8/3/2015)... Aug. 3, 2015   Intrexon Corporation (NYSE: ... half and second quarter 2015 financial results after the ... The Company will host a conference call at 5:30 ... general business update. The conference call may ... (International), and asking to join the "Intrexon Corporation Call."  ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... competitive market analysis and premium industry insights on the global resorcinol industry. The ... a collective study of vivid market scenarios and analysis of primary and secondary ...
(Date:7/30/2015)... 30, 2015   GenoSpace , a leading ... and analysis of genomic and other biomedical data, ... joined the company as Vice President of Sales ... "GenoSpace partners with its ... analyze and explore complex sets of genomic, phenotypic ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
Breaking Biology Technology:Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... Call and Webcast on March 14 at 8:00 a.m. PDT ... ... March 13 Halozyme Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical company ... three months and year ended December 31, 2007., "Our achievements in ...
... 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI ... entered into a,definitive licensing agreement with privately held ... to market and distribute the,Option(TM) inferior vena cava ... the body,s inferior vena cava to prevent pulmonary ...
... EMERYVILLE, Calif., March 13 Bionovo, Inc.,(Nasdaq: ... Butler, Ph.D., to,the company,s Board of Directors. Dr. ... companies, and in particular in,advancing cancer drug development ... to have George on board as we move ...
Cached Biology Technology:Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 2Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 4Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 5Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 6Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 7Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 8Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter 2Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter 3Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter 4Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter 5Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter 6George Butler Joins Bionovo's Board of Directors 2George Butler Joins Bionovo's Board of Directors 3
...
CQCS kit for etra KR 4i , (other units)....
... Magnetic Stirrers operate without any moving parts ... making VARIOMAG Magnetic Stirrers 100% wear-free and ... can be hermetically sealed, making it inaccessible ... why VARIOMAG Magnetic Stirrers are particularly suitable ...
... Fluoroskan Ascent FL is ... and luminometric measurement technologies ... list of advanced features ... Luminoskan Ascent. Fluoroskan Ascent ...
Biology Products: